Article
Critical Care Medicine
Vidushi Sood, Linda Rogers, Sandhya Khurana
Summary: Oral corticosteroid (OCS) use in severe asthma is still common despite advances in treatment, but monoclonal antibodies have been developed to reduce OCS-treated exacerbations. Strategies for managing endocrine complications associated with OCS use include identifying OCS-dependent patients, optimizing OCS dose, tapering OCS based on asthma control criteria, assessing adrenal axis integrity, and managing corticosteroid-related comorbidities.
Article
Immunology
Jose M. Rodrigo-Munoz, Marta Gil-Martinez, Clara Lorente-Sorolla, Raquel Garcia-Latorre, Marcela Valverde-Monge, Santiago Quirce, Joaquin Sastre, Victoria del Pozo
Summary: MicroRNA miR-144-3p is identified as a potential diagnostic biomarker for severe asthma, as its expression is associated with the severity of the disease and corticosteroid treatment. It is increased in asthmatic lungs and serum, correlating with blood eosinophilia and genes involved in asthma pathophysiology. This miRNA shows promise as a novel biomarker for severe asthma previously treated with higher doses of corticosteroids.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Medicine, General & Internal
M. Gurnell, L. G. Heaney, D. Price, A. Menzies-Gow
Summary: Secondary adrenal insufficiency often results from excessive exogenous corticosteroid therapy, particularly oral corticosteroids. Biologic therapies offer a potential solution for reducing or eliminating maintenance OCS in severe asthma, but there is a need for further clinical trials to define strategies for early identification and treatment of AI, as well as safe OCS withdrawal in routine practice.
JOURNAL OF INTERNAL MEDICINE
(2021)
Article
Allergy
Christian Domingo, Jorge F. Maspero, Mario Castro, Nicola A. Hanania, Linda B. Ford, David M. G. Halpin, David J. Jackson, Nadia Daizadeh, Michel Djandji, Colin P. Mitchell, Nora Crikelair, Juby A. Jacob-Nara, Yamo Deniz, Paul J. Rowe, Benjamin Ortiz
Summary: The study analyzed the efficacy of Dupilumab in patients with OCS-dependent severe asthma, showing that Dupilumab can significantly reduce OCS dose, improve the likelihood of no longer needing OCS, reduce exacerbations, and improve lung function.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
(2022)
Review
Allergy
Yan Xie, Peter W. Abel, Thomas B. Casale, Yaping Tu
Summary: Asthma can be classified into T2 and non-T2 types, with non-T2 asthma being more severe and often unresponsive to treatment. Recent studies suggest that non-T2 asthma is associated with T(H)17 cell immune responses, which may contribute to corticosteroid insensitivity in asthma.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2022)
Article
Respiratory System
Christian Domingo, Klaus F. Rabe, David Price, Guy Brusselle, Michael E. Wechsler, Changming Xia, Nami Pandit-Abid, Rebecca Gall, Paul J. Rowe, Yamo Deniz, Juby A. Jacob-Nara, Amr Radwan
Summary: This post hoc analysis evaluates the long-term effects of dupilumab on severe OCS-dependent asthma, and finds that it improves clinical outcomes and reduces OCS dose irrespective of baseline disease severity.
Article
Allergy
Carlos Cardoso-Vigueros, Tobias von Blumenthal, Beate Rueckert, Arturo O. Rinaldi, Ge Tan, Anita Dreher, Urszula Radzikowska, Gunter Menz, Peter Schmid-Grendelmeier, Cezmi A. Akdis, Milena Sokolowska
Summary: This study aimed to determine the utility of leukocyte redistribution as a biomarker of disease heterogeneity in patients with severe asthma and as a bioindicator of potential corticosteroid resistance. Through clinical data analysis and flow cytometry, we identified two clusters of severe asthma patients with differences in cell frequencies, response to corticosteroids, and atopy status.
CLINICAL AND EXPERIMENTAL ALLERGY
(2022)
Article
Emergency Medicine
Soudani Marghli, Chafiaa Bouhamed, Amira Sghaier, Nabil Chebbi, Insaf Dlala, Samia Bettout, Achref Belkacem, Sarra Kbaier, Nahla Jerbi, Abdelouahab Bellou
Summary: This study aimed to assess the effect of high and repeated doses of inhaled budesonide when combined with the standard treatment of adult acute asthma. The results showed that the combination of inhaled budesonide with hydrocortisone had no additional effect over the use of hydrocortisone alone.
BMC EMERGENCY MEDICINE
(2022)
Article
Multidisciplinary Sciences
Sofina Begum, Blair Z. Johnson, Aude-Claire Morillon, Rongchang Yang, Sze How Bong, Luke Whiley, Nicola Gray, Vanessa S. Fear, Leila Cuttle, Andrew J. A. Holland, Jeremy K. Nicholson, Fiona M. Wood, Mark W. Fear, Elaine Holmes
Summary: The study suggests that non-severe burn trauma in children may leave a sustained immunometabolic imprint, potentially linked to long-term immune changes that may contribute to poor long-term health outcomes observed in children after burn injury.
SCIENTIFIC REPORTS
(2022)
Article
Clinical Neurology
Chenglong Li, Yanjun Ma, Rong Hua, Zhenchun Yang, Baoliang Zhong, Hongyu Wang, Wuxiang Xie
Summary: The study found a significant association between higher long-term blood pressure variability and accelerated cognitive decline, with a nonlinear dose-response relationship. Further randomized controlled trials are needed to assess the potential benefits of strategies aimed at reducing blood pressure variability for cognitive health.
Article
Environmental Sciences
Stephen P. Uong, Haider Hussain, Erin Thanik, Stephanie Lovinsky-Desir, Jeanette A. Stingone
Summary: In cross-sectional studies like NHANES, researchers have found positive associations between PAH exposure and asthma diagnosis. This study examined the relationship between markers of recent PAH exposure and short-term asthma medication use. The results showed a positive association between PAH exposure markers and SABA or systemic corticosteroid use.
ENVIRONMENTAL RESEARCH
(2023)
Article
Allergy
Fahad H. Alahmadi, Brian Keevil, Lynn Elsey, Kate George, Robert Niven, Stephen J. Fowler
Summary: LC-MS/MS can reliably detect commonly used ICSs in the blood at least 8 hours after dosing, providing a measure of adherence in severe asthma patients. Lower blood levels were associated with higher exacerbation rates and poorer lung function.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
(2021)
Article
Critical Care Medicine
Lawrence D. Sher, Michael E. Wechsler, Klaus F. Rabe, Jorge F. Maspero, Nadia Daizadeh, Xuezhou Mao, Benjamin Ortiz, Leda P. Mannent, Elizabeth Laws, Marcella Ruddy, Nami Pandit-Abid, Juby A. Jacob-Nara, Rebecca Gall, Paul J. Rowe, Yamo Deniz, David J. Lederer, Megan Hardin
Summary: This study found that in patients with severe OCS-dependent asthma, dupilumab treatment can maintain long-term reduction in OCS usage and demonstrate improvements in lung function and asthma control.
Review
Respiratory System
Raja Dhar, Chin Kook Rhee, Diahn-Warng Perng, Koichi Fukunaga, Mary Sau-Man Ip, Siwasak Juthong, Mariko Siyue Koh, Jing Li, Shubham Sharma, Wiwien Heru Wiyono
Summary: Most patients with asthma can manage their condition effectively with inhaled medications. However, those with severe or uncontrolled asthma may require systemic corticosteroids, which can have long-term adverse health outcomes. Studies suggest that there is an overuse of systemic corticosteroids in asthma management globally, including Asia, and coordinated changes are needed to reduce this burden.
Article
Allergy
Charles Pilette, Giorgio Walter Canonica, Rekha Chaudhuri, Geoffrey Chupp, F. Eun-Hyung Lee, Jason Kihyuk Lee, Carlos Almonacid, Tobias Welte, Rafael Alfonso-Cristancho, Rupert W. Jakes, Aoife Maxwell, Robert G. Price, Peter Howarth
Summary: This 1-year analysis demonstrates that real-world mepolizumab treatment is clinically effective in patients with severe asthma, providing disease control while reducing the need for mOCS and SCS bursts.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
(2022)
